Inventor · disambiguated record
Scott Ronald Brodeur
Also filed as: BRODEUR SCOTT · BRODEUR SCOTT R · BRODEUR SCOTT RONALD
15 granted patents·14 pending applications·103 citations·filing 2011–2024
91Inventor score
Files withBOEHRINGER INGELHEIM INT18JANSSEN BIOTECH INC5BRISTOL MYERS SQUIBB CO3BARRETT RACHEL REBECCA2JANSSEN PHARMACEUTICA NV1
Top patents by PatentIndex Score
29 records- 0196US8591900B2Anti-CD40 antibodiesBARRETT RACHEL REBECCA·Filed 2011·Granted Nov 26, 2013·53 cites·42 claims
- 0295US11008395B2Antibodies against IL-7R alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2020·Granted May 18, 2021·5 cites·25 claims
- 0395US9090696B2Polynucleotides encoding anti-CD40 antibodiesBARRETT RACHEL REBECCA·Filed 2013·Granted Jul 28, 2015·33 cites·4 claims
- 0491US12084501B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2022·Granted Sep 10, 2024·2 cites·44 claims
- 0586US11242394B2Anti-CD40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2018·Granted Feb 8, 2022·3 cites·43 claims
- 0681US11795219B2Antibody molecules for cancer treatmentBOEHRINGER INGELHEIM INT·Filed 2020·Granted Oct 24, 2023·1 cites·38 claims
- 0781US10793629B2Compound targeting IL-23A and TNF-alpha and uses thereofBOEHRINGER INGELHEIM INT·Filed 2018·Granted Oct 6, 2020·1 cites·35 claims
- 0879US2023382988A1Compound targeting il-23a and tnf-alpha and uses thereofBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 0979US2022153857A1Anti-cd40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 1078US2024417478A1Antibodies against il-7r alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1177US10059763B2Compound targeting IL-23A and TNF-alpha and uses thereofBOEHRINGER INGELHEIM INT·Filed 2015·Granted Aug 28, 2018·2 cites·23 claims
- 1275US11028169B2Antibody molecules for cancer treatmentBOEHRINGER INGELHEIM INT·Filed 2017·Granted Jun 8, 2021·1 cites·67 claims
- 1375US2025145711A1Proteins comprising cd3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1474US10377804B2Anti-BAFF antibodiesBOEHRINGER INGELHEIM INT·Filed 2017·Granted Aug 13, 2019·1 cites·10 claims
- 1574US2024124581A1Antibody molecules for cancer treatmentBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 1671US11919962B2Antibodies against IL-7R alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·0 cites·29 claims
- 1771US11680096B2Compound targeting IL-23A and TNF-alpha and uses thereofBOEHRINGER INGELHEIM INT·Filed 2020·Granted Jun 20, 2023·0 cites·25 claims
- 1867US9840543B2Anti-BAFF antibodiesBOEHRINGER INGELHEIM INT·Filed 2015·Granted Dec 12, 2017·1 cites·15 claims
- 1965US11370818B2Anti-BAFF antibodiesBOEHRINGER INGELHEIM INT·Filed 2019·Granted Jun 28, 2022·0 cites·8 claims
- 2065US2023265203A1Use of anti-cd40 antibodies for treatment of lupus nephritisBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 2161US2017058039A1Anti-cd40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2016·Application pending·0 cites
- 2260US2016222124A1Anti-cd40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2016·Application pending·0 cites
- 2359US12460001B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2021·Granted Nov 4, 2025·0 cites·50 claims
- 2457US2015315282A1Anti-cd40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2015·Application pending·0 cites
- 2557US2024059789A1Psma binding proteins and uses thereofJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2657US2022267438A1Trispecific antibody targeting bcma, gprc5d, and cd3JANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 2756US2024025992A1Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their usesJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2847US2019177420A1Use of anti-cd40 antibodies for treatment of lupus nephritisBOEHRINGER INGELHEIM INT·Filed 2018·Application pending·0 cites
- 2941US2017058038A1Use of anti-cd40 antibodies for treatment of lupus nephritisBOEHRINGER INGELHEIM INT·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Scott Ronald Brodeur files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →